Hideto Iwamoto1, Shuichi Morizane2, Takuya Koie3, Ryoichi Shiroki4, Mutsushi Kawakita5, Tatsuo Gondo6, Kazumasa Matsumoto7, Tomonori Habuchi8, Hiroshi Sunada9, Yusuke Endo9, Hisashi Noma10, Atsushi Takenaka2, Hiroomi Kanayama11. 1. Division of Urology, Department of Surgery, Tottori University Faculty of Medicine, 86 Nishi-cho, Yonago, Tottori, 683-8504, Japan. gakkoura@med.tottori-u.ac.jp. 2. Division of Urology, Department of Surgery, Tottori University Faculty of Medicine, 86 Nishi-cho, Yonago, Tottori, 683-8504, Japan. 3. Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. 4. Department of Urology, Fujita Health University, Toyoake, Japan. 5. Department of Urology, Kobe City Medical Center General Hospital, Kobe, Japan. 6. Department of Urology, Tokyo Medical University, Tokyo, Japan. 7. Department of Urology, Kitasato University School of Medicine, Sagamihara, Japan. 8. Department of Urology, Akita University School of Medicine, Akita, Japan. 9. Advanced Medicine, Innovation and Clinical Research Center, Tottori University Hospital, Tottori, Japan. 10. Department of Data Science, The Institute of Statistical Mathematics, Tokyo, Japan. 11. Department of Urology, Tokushima University Graduate School, Tokushima, Japan.
Abstract
BACKGROUND: To determine the peri-operative safety and oncological value of robotic-assisted radical cystectomy (RARC) for older and younger patients in an initial Japanese RARC series. METHODS: We retrospectively analyzed the demographics, complications, peri-operative and oncological outcomes of 253 consecutive patients with bladder cancer who underwent RARC at 34 institutions in Japan between April 2009 and March 2017. The patients were assigned to groups according to ages at surgery of < 70 (younger; n = 125) and ≥ 70 (older; n = 128) years. RESULTS: Mean Charlson comorbidity index (p = 0.045) and the incidence of a history of previous abdominal surgery (p = 0.002) were significantly higher, whereas a history of neoadjuvant chemotherapy (p = 0.028) and neobladder (p < 0.001) were significantly lower in the older group. Mean total operative time was significantly shorter (p = 0.019) and mean estimated blood loss (p = 0.013) was significantly lower in the older group. Post-operative Grade ≥ II complications were comparable at 0-30, 31-90 and 91 days after surgery despite urinary tract associations. Rates of positive surgical margins and mean numbers of removed lymph nodes were comparable between the two groups. Although 5-year overall survival rates were significantly lower (p = 0.03) for older patients, 5-year cancer-specific (p = 0.10) and recurrence-free survival rates were comparable (p = 0.20) between the groups. CONCLUSION: Using RARC potentially allows the application of less invasive procedures and cancer control for septuagenarian patients that are equivalent to those for younger patients.
BACKGROUND: To determine the peri-operative safety and oncological value of robotic-assisted radical cystectomy (RARC) for older and younger patients in an initial Japanese RARC series. METHODS: We retrospectively analyzed the demographics, complications, peri-operative and oncological outcomes of 253 consecutive patients with bladder cancer who underwent RARC at 34 institutions in Japan between April 2009 and March 2017. The patients were assigned to groups according to ages at surgery of < 70 (younger; n = 125) and ≥ 70 (older; n = 128) years. RESULTS: Mean Charlson comorbidity index (p = 0.045) and the incidence of a history of previous abdominal surgery (p = 0.002) were significantly higher, whereas a history of neoadjuvant chemotherapy (p = 0.028) and neobladder (p < 0.001) were significantly lower in the older group. Mean total operative time was significantly shorter (p = 0.019) and mean estimated blood loss (p = 0.013) was significantly lower in the older group. Post-operative Grade ≥ II complications were comparable at 0-30, 31-90 and 91 days after surgery despite urinary tract associations. Rates of positive surgical margins and mean numbers of removed lymph nodes were comparable between the two groups. Although 5-year overall survival rates were significantly lower (p = 0.03) for older patients, 5-year cancer-specific (p = 0.10) and recurrence-free survival rates were comparable (p = 0.20) between the groups. CONCLUSION: Using RARC potentially allows the application of less invasive procedures and cancer control for septuagenarian patients that are equivalent to those for younger patients.
Authors: Giacomo Novara; James W F Catto; Timothy Wilson; Magnus Annerstedt; Kevin Chan; Declan G Murphy; Alexander Motttrie; James O Peabody; Eila C Skinner; Peter N Wiklund; Khurshid A Guru; Bertram Yuh Journal: Eur Urol Date: 2015-01-02 Impact factor: 20.096
Authors: Bertram Yuh; Timothy Wilson; Bernie Bochner; Kevin Chan; Joan Palou; Arnulf Stenzl; Francesco Montorsi; George Thalmann; Khurshid Guru; James W F Catto; Peter N Wiklund; Giacomo Novara Journal: Eur Urol Date: 2015-01-02 Impact factor: 20.096
Authors: S Machele Donat; Timothy Siegrist; Angel Cronin; Caroline Savage; Matthew I Milowsky; Harry W Herr Journal: J Urol Date: 2010-06 Impact factor: 7.450
Authors: Robert M Coward; Angela Smith; Mathew Raynor; Matthew Nielsen; Eric M Wallen; Raj S Pruthi Journal: Urology Date: 2011-02-18 Impact factor: 2.649
Authors: Bernard H Bochner; Guido Dalbagni; Daniel D Sjoberg; Jonathan Silberstein; Gal E Keren Paz; S Machele Donat; Jonathan A Coleman; Sheila Mathew; Andrew Vickers; Geoffrey C Schnorr; Michael A Feuerstein; Bruce Rapkin; Raul O Parra; Harry W Herr; Vincent P Laudone Journal: Eur Urol Date: 2014-12-08 Impact factor: 20.096
Authors: Hamid Abboudi; Mohammed Shamim Khan; Khurshid A Guru; Saied Froghi; Gunter de Win; Hendrik Van Poppel; Prokar Dasgupta; Kamran Ahmed Journal: BJU Int Date: 2013-10-24 Impact factor: 5.588